Revolutionizing Hematology Research with AI Solutions
ConcertAI and NeoGenomics have embarked on an innovative journey to enhance hematological cancer research through their newly announced AI software-as-a-service (SaaS) solution. By combining their expertise, the two companies aim to bolster research analytics, clinical trial design, and operational optimization for hematological malignancies. This groundbreaking solution, known as CTO-H, emerges as an unprecedented offering tailored for the complexities of hematology.
Understanding the CTO-H Solution
CTO-H stands out due to its expansive research data capabilities, offering unparalleled scale, longitudinal analysis, and integration of detailed biomarker data. With a database representing over 370,000 patient journeys documented over a span of 7 to 11 years, this solution is considered the largest established reference dataset for hematological malignancies to date. The meticulous depth of information available promises to be revolutionary for healthcare providers and biopharmaceutical firms navigating the challenges associated with clinical trials.
User-Centric Design in Clinical Trials
As the landscape of hematology treatments evolves rapidly, the need for precise patient stratification in clinical trials has never been greater. Both companies recognize the criticality of defining appropriate patient populations, especially during the early phases of trial design. Consequently, CTO-H integrates user-centric design, helping researchers to refine their strategies and methodologies.
Addressing Challenges in Research
The sheer complexity of hematology research often complicates trial execution. The growing variety of treatment options and the intricate dynamics of patient populations increase the difficulty of maintaining representative control groups in late-phase trials. CTO-H proposes solutions by leveraging comprehensive data to improve accrual processes efficiently.
Insights from Industry Leaders
Jeff Elton, PhD, the founding CEO of ConcertAI, articulates the complexity of hematological research, highlighting the variability of treatments and the extended duration of treatment courses that lead to relapses. He asserts that CTO-H's multi-modal approach represents a breakthrough in clinical analysis and planning, fostering a new era in study optimization.
Lindsey Gasparini, the Vice President of Informatics at NeoGenomics, underscores the extensive capabilities provided by this joint effort. With NeoGenomics offering more than 500 clinical diagnostic tests, particularly in hematology, the company's commitment to this project ensures that biopharma partners will greatly benefit from enhanced precision in trial design and execution.
Future Availability and Impact
The CTO-H solution will be deployed as part of ConcertAI's CARAai™ cloud platform. As the collaboration moves forward, NeoGenomics will contribute its specialized biomarker testing services, ensuring that clients receive the most accurate analyses and study designs. Currently, CTO-H is available in a pre-release form, with full capabilities set to launch in early 2025.
About ConcertAI
ConcertAI is a leader in generative and predictive AI, focusing on real-world data research solutions tailored for healthcare and life sciences. The organization's mission is straightforward: to accelerate insights and outcomes for patients by providing research-ready data, cutting-edge technologies, and seasoned expertise while collaborating with over 46 leading biomedical innovators, 2,000 healthcare providers, and various medical societies. ConcertAI also integrates advanced imaging technologies with TeraRecon® and offers vital oncology services via CancerLinQ®, ensuring comprehensive support for healthcare professionals across numerous platforms. Headquartered in a vibrant hub of technological advancement, ConcertAI continues to push boundaries in patient-centered research.
Frequently Asked Questions
What is CTO-H?
CTO-H is a software-as-a-service solution developed by ConcertAI and NeoGenomics aimed at improving research analytics and clinical trial design for hematological malignancies.
What companies collaborated on this solution?
The collaboration was between ConcertAI and NeoGenomics, leveraging their expertise in AI and clinical diagnostics.
What is the significance of the dataset used in CTO-H?
The dataset comprises information from over 370,000 patient journeys, making it the largest reference dataset in the field of hematological malignancies.
When will CTO-H be fully available?
CTO-H is set for general availability on January 17, 2025, following its pre-release evaluation phase.
How will CTO-H impact clinical trials?
CTO-H aims to refine clinical trial design and execution by providing greater precision and reducing the time needed in the overall clinical development process, ultimately accelerating innovations in the field.
